Spring Bank Pharmaceuticals, Inc. announced the appointment of Dr. Todd C. Brady to the company's Board of Directors, effective July 28, 2016. Dr. Brady currently serves as Chief Executive Officer, President and Director of Aldeyra Therapeutics. Dr. Brady brings to the Bank Board of Directors a wealth of experience across the full spectrum of drug development and biopharmaceutical management. His insights will also be invaluable in relation to plans to explore and pursue SB 9200 in other viral indications and advance earlier stage compounds in the areas of inflammation and oncology. Dr. Brady was appointed President and Chief Executive Officer of Aldeyra Therapeutics in 2012, having been a member of the Board of Directors since 2005.